Zhejiang Wolwo Bio-Pharmaceutical Co Ltd300357
▲ PositiveCapitalrelevance
Interim net profit of 213 million yuan reported, indicating strong profitability.
Impact on stocks 1
Others
Zhejiang Wolwo Bio-Pharmaceutical Co LtdWolwo Bio released its 2026 interim report, showing total operating revenue of 514 million yuan and net profit attributable to the parent company of 213 million yuan. Net cash inflow from operating activities was 190 million yuan, a decrease of 11.008 million yuan compared with the same period last year, down 5.49 percent year on year. The company's asset-liability ratio was 7.71 percent, gross margin was 95.29 percent, return on equity was 7.75 percent, and diluted earnings per share was 0.41 yuan. The number of shareholders was 35,300, and the top ten shareholders held 54.76 percent of the total share capital.
Zhejiang Wolwo Bio-Pharmaceutical Co LtdInterim net profit of 213 million yuan reported, indicating strong profitability.